Member Info for Hurst10

Another Evidence of double vaccinated being able to pass on the virus.

https://els-jbs-prod-cdn.jbs.elsevierhealth.com/pb-assets/Lancet/pdfs/s1473309921006484-1635425926927.pdf

Agree and would not be surprised if we have a preliminary RNS trial update before year end and obviously the market will not be surprised and will remind them of how big market the market is!
GSK,AZN,BMY and Abbott US combined spend more money annually on in House staff catering globally,than the market cap of Avacta !
They will be lining up!!!
I hope we will see the company with the support of the shareholders proceed to dual listing or break up with Therapeutics heading for Nasdaq.
Anyway it could be a very interesting year end.

Over 75 per cent of Denmark’s 5.8 million inhabitants have been fully vaccinated.

Despite the fact that 85 per cent of people over the age of 12 are vaccinated, Denmark has seen more than 1,000 daily cases of COVID for a week straight.

Now authorities are threatening to “shut down society,” according to opposition party health spokesman Martin Geertsen, if more Danes don’t take the shot.

“If we are to keep Denmark open, we must have more people get the vaccine,” said Health Minister Magnus Heunicke

Meanwhile, Denmark the latest country in Europe, who are turning up testing capacity at their facilities by 50%, due to surge in demand, very much because of demand from teenagers and even younger children.
Abbott’s, Antigen,Quidel and Roche are all talking the same story, they all are packed up late summer,believing it was all sorted in the Western World,only for a new variant of the virus to return.They got caught out and now demand is not the problem, but supply!
With the UK Gov implementing much stricter quality conditions on LFT tests to remain or be approved to their list of travellers etc, that will reduce demand for some of the more colourful lower quality Asian variations. Everybody has been very impatient with Avacta, but surely we must all agree that the company is sitting on a “goldmine of various opportunities”.
SARS-CoV-2 Antigen Lateral Flow tests, Precision tumour targeted Chemotherapy, gene and cell therapy and radio pharmaceuticals.
The company is waiting to be broken up and as I have said before,it is very unlikely that Astra Zeneca is going stand by and watch an overseas company walk away with
“ one of the best things out of Cambridge “ since Arm Holdings, and break it up.
The Precision Oncology market valuation alone going forward will be well beyond any previous estimates.

The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties!
Shows you the interest and valuation in the area
Avacta’s lead Affimer® programme is a PD-L1 antagonist which will form the basis of future bispecifics, immunocytokines and TMAC drug conjugates. The lead pre|CISION™ programme is a tumour targeted form of Doxorubicin

The majors are and will be knocking on the door, once we have a preliminary phase one trial update.
So far we have had only indication from the management during investor presentations post result that he is very happy with the ongoing trials.Have not suggested that anything has gone wrong so far and off course hospitals are lining up to participate .
218 rather than 118

With regards to Professional use, it is clear that group self testing under supervision of a professional appointed person is allowed.This could mean Airports, Airport Bus terminals etc. Having a large group of people conducting the test them selves!
Training and competency assessment
For information on what an appropriate training programme and competency assessment for professional users of COVID-19 tests should include, manufacturers and testing service providers should refer to the BSI Standards Publication PD ISO/TS 22583:2019 “Guidance for supervisors and operators of point of care testing (POCT) devices”. The MHRA recommends that there shall be an appointed person(s) (supervisor) who has the authority and takes responsibility for the quality of the service and is competent to supervise the testing and training of other professional users.

After completing the training programme professional users should

have demonstrated ability to apply knowledge and skills to produce an accurate POCT result
have an understanding of the testing requirements and be able to assess the appropriateness and suitability of the person to be tested
be able to perform tests following the manufacturers’ instructions for use, including quality control checks, operating environment and reagent storage
have an understanding of interference factors. For example, a substance or process which falsely alters a test result
be able to demonstrate safe and accurate results reporting and interpretation
have an understanding of quality assurance activities and be able to detect erroneous results and take appropriate action
The training should include a competency assessment to check for understanding and correct performance of the test.

With all the quality requirements with the LFT, looks like the Government very cleverly have filtered out the cheaper versions ie. Chinese to make room for high quality CE marked LFT.Abingdon etc are manufacturing as we are speaking.

So CE marked can sell ?

200,000 bought at 122.50

Quest Diagnostics Reports Third Quarter 2021 Financial Results, Raises Outlook for Full Year 2021

Note who is constantly best bid and with US hours and positive COVID testing outlook from Roche and Abbott? over the last hour, expect solid buying this afternoon.

More from the sector

Abbott raises 2021 guidance following strong growth for COVID-19 tests

Roche investor update :
Basel, 20 October 2021
Roche reports strong growth in the first nine months – outlook for 2021 raised
?
CEO Severin Schwan on the results: “The demand for coronavirus tests remained high in the third quarter due to the Delta variant. Together with the recently launched medicines and diagnostics platforms they contributed to the strong sales growth. We also made significant progress in our product pipeline in the third quarter, including with Polivy, the first medicine in 20 years to significantly improve outcomes in a form of aggressive blood cancer. Based on the results achieved so far, we are raising our outlook for the full year.”
Outlook raised for 2021
Sales are now expected to grow in the mid-single digit range, at constant exchange rates (before: in the low to mid-single digit range). Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to increase its dividend in Swiss francs further

Early risers in NY and we have buyers resuming getting involved!

I very much agree with regards to a potential listing of the Therapeutics division or a third party bidding for that part of the business.
The valuation will off course be subject to AVA6000 etc. but it is very clear in this case “ Silence is golden “ as the management have not come out with any comment on the existing phase one trial, which suggest to me that we are still doing well and with Leeds now coming up with trials we could potentially be on to something very big and as I have mentioned before, Avacta could be the next big thing out of Cambridge since Arm Holdings, , but AZN would very much like Avacta to remain British rather that Roche etc stepping in with a nice upfront payment and subsequent milestone payments which could easily run into billions. Meanwhile the Diagnostic division could have an interesting week.
Note every afternoon we have repetitive buying in blocks and post market prints. Would suggest we already have US buyers stepping up the game.

Apologies if posted already :

Further to the news from Wolverhampton, now 400,000 were processed and second site.
The errors relate to test results given to people between 8 September and 12 October, mainly in the southwest of England. It is estimated that around 400,000 samples have been processed through the lab. A full investigation is being carried out into why incorrect results were given, NHS Test and Trace said. It is now contacting the people who could still be infectious to advise them to take another test. Close contacts who are symptomatic will also be advised to take a test, as is already recommended.
Problems have also been identified at the Newbury Showground testing site in Berkshire. West Berkshire Council said some negative results may have been given incorrectly. Anyone who got a negative result at the site between 3 and 12 October has been urged to take another test.
400,000 samples being tested and second site in Berkshire.
Read more: https://www.newscientist.com/article/2237475-covid-19-news-valneva-reports-positive-results-from-vaccine-trial/#ixzz79eg09AZb

Since around 07.00 AM NY time, we have had 6 or 7 25/ trades going through, much more to come. Current MM on best bid has a 10p spread!

Usual post market size orders

Live Updates: Italy’s Covid Vaccine Mandate Comes Into Force, a First for a Western Democracy
All workers across public and private sectors are now required to be vaccinated or take frequent coronavirus tests. While many accepted the move as a necessity, it was greeted by protests in some parts of the country.